Media stories about Syndax Pharmaceuticals (NASDAQ:SNDX) have trended somewhat positive on Monday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1191049445719 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several analysts recently issued reports on SNDX shares. Instinet reiterated a “buy” rating and set a $22.00 price target (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. Citigroup set a $20.00 price target on shares of Syndax Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Nomura reduced their price target on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 11th. Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Oppenheimer raised their target price on shares of Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Syndax Pharmaceuticals presently has an average rating of “Buy” and an average price target of $23.13.

Shares of Syndax Pharmaceuticals (SNDX) traded down $0.47 during trading on Monday, reaching $8.29. 177,300 shares of the company’s stock were exchanged, compared to its average volume of 158,000. Syndax Pharmaceuticals has a 1 year low of $6.31 and a 1 year high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.12. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.30 million. During the same quarter last year, the business posted ($0.84) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts expect that Syndax Pharmaceuticals will post -3.03 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/04/syndax-pharmaceuticals-sndx-receiving-somewhat-positive-news-coverage-study-finds.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.